Combination chemotherapy for colorectal cancer that cannot be removed with surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs—chemotherapy plus two targeted therapies—as a first treatment for colorectal cancer that cannot be surgically removed. The goal is to shrink tumors enough to allow surgery later, potentially improving outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that has spread or come back and cannot be removed with surgery at this time.
- You have not had any previous treatment for colorectal cancer with chemotherapy or other systemic therapies.
- Your tumor is a type called pMMR or MSS (your doctor can check this).
- You are in good overall health with a performance status of 0 or 1 (able to do daily activities).
- You have at least one measurable tumor and adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two newer drugs plus chemotherapy as the first treatment for people with advanced colorectal cancer that has a RAS or BRAF gene change. The goal is to see if this combination helps shrink tumors and slow the cancer.
This trial studies fruquintinib combined with serplulimab (an immune therapy) for advanced colorectal cancer that has spread and is no longer responding to standard treatments. It may help by slowing the cancer’s growth and improving outcomes after the usual options have been tried.
This trial tests a new immunotherapy drug called serplulimab combined with standard chemotherapy or targeted therapy for colorectal cancer that has come back within a year after surgery. The goal is to see if adding this immune-boosting drug helps control the cancer better than chemotherapy alone.
This trial tests a combination of two drugs and a liver-directed therapy for people with advanced colorectal cancer that has spread to the liver. It aims to see if this approach can help when standard first-line treatment has stopped working.
This trial tests a new combination of drugs for people with advanced colorectal cancer that has not responded to standard treatments. The drugs may help your immune system fight the cancer and block its growth.
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
Hear when a new Colorectal Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.